Delcath Systems

DCTH (NasdaqCM)

Delcath Systems is an interventional oncology company focused on treating primary and metastatic liver cancers in the United States and Europe. Its lead product, HEPZATO KIT, delivers melphalan directly to the liver, aiming to provide high-dose chemotherapy while limiting whole-body exposure. HEPZATO is also evaluated in the FOCUS trial for metastatic hepatic-dominant uveal melanoma. The company also supplies CHEMOSAT hepatic delivery systems for European liver cancer care. Founded in 1988, it is based in Queensbury, New York.